A news story featuring how Dr. Douglas Gould’s work lead to the opening of the world’s first center of excellence to help families of children with Gould Syndrome is featured on UCSF’s News!
We are pleased to announce a story about the opening of the First Center of Excellence for Gould Syndrome, featuring our Dr. Douglas Gould and his research efforts leading to this new center to help families with children affected by this rare genetic disorder. This center is also includes pediatric ophthalmologist Dr. Alejandra de Alba Campomanes and is the culmination of years of Dr. Gould’s research group’s translational research work to understand the biological functions of a multi-system disorder that is caused by mutations in the genes encoding type IV collagen alpha 1 (COL4A1) and COL4A2. Dr. Gould is a Professor of Ophthalmology and Anatomy and a member of the Institute for Human Genetics, Bakar Aging Research Institute, and Cardiovascular Research Institute.
Learn more about their research here: https://ophthalmology.ucsf.edu/gouldlab/ and read the exciting full news story here: https://www.ucsf.edu/news/2024/02/427141/ucsf-opens-worlds-first-center-excellence-gould-syndrome
Project Title: Elucidating Mechanisms of Visual Pathway Damage in Alzheimer’s Disease
Project Title: Mechanisms of Retinal Degeneration in Alzheimer’s Disease-Related Dementias
Project Title: Enabling Direct Correlation of Choroidal Blood Flow and Retinal Degeneration at the Single Vessel Level and Over Time Using Transscleral Multiphoton Microscopy
Project Title: Transcutaneous Orbicularis Oculi Stimulation for Temporary Eyelid Closure
Development of an injectable biopolymer device for sustained intravitreal delivery of carbonic anhydrase inhibitor for the treatment of juvenile X-linked retinoschisis.
Juvenile X-linked retinoschisis (XLRS) is an inherited retinal disorder (IRD) that predominantly affects boys and men, arising in early childhood with potential blindness by their teens or adulthood. While there are few medication options for IRDs, XLRS responds well to carbonic anhydrase inhibitor (CAI) treatment. Treatment with eye drops has been effective but is unable to fully penetrate the eye and dependent on patient application. This project aims to develop a minimally invasive injectable device to provide CAI therapy for 6–12 months, offering a better treatment approach.
Deep learning system to predict 5-year risk of high myopia using fundus imaging in a North American population of children.
Multiphoton Aqueous Flowmetry and Image-Guided Laser Therapy: Novel Approaches for Glaucoma Precision Medicine. 
